235 related articles for article (PubMed ID: 11862422)
1. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
[TBL] [Abstract][Full Text] [Related]
2. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
5. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
Steller MD; Shaw TJ; Vanderhyden BC; Ethier JF
Mol Cancer Res; 2005 Jan; 3(1):50-61. PubMed ID: 15671249
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
7. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
Tanaka T; Toujima S; Utsunomiya T; Yukawa K; Umesaki N
Oncol Rep; 2008 Jul; 20(1):13-23. PubMed ID: 18575713
[TBL] [Abstract][Full Text] [Related]
8. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring impact of measurement of urinary beta-human chorionic gonadotropin on orthotopic implantation model of human ovarian carcinoma in athymic nude mice].
Li J; Xing H; Gao QL; Lu YP; Wang SX; Zhang AL; Xi L; Ma D
Ai Zheng; 2002 Sep; 21(9):949-53. PubMed ID: 12508539
[TBL] [Abstract][Full Text] [Related]
10. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
11. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
[TBL] [Abstract][Full Text] [Related]
13. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
14. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Wiener JR; Nakano K; Kruzelock RP; Bucana CD; Bast RC; Gallick GE
Clin Cancer Res; 1999 Aug; 5(8):2164-70. PubMed ID: 10473101
[TBL] [Abstract][Full Text] [Related]
15. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
16. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
17. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
18. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo.
Bottero F; Tomassetti A; Canevari S; Miotti S; Ménard S; Colnaghi MI
Cancer Res; 1993 Dec; 53(23):5791-6. PubMed ID: 8242637
[TBL] [Abstract][Full Text] [Related]
19. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
20. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]